Investor mix
7 investors on record; lead investors include Suvretta Capital Management.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 1 | 14% |
| Private equity | 2 | 29% |
| Other / undisclosed | 4 | 57% |
Developer of novel biological targets and drugs for the treatment of rare metabolic disorders and NASH
7 investors on record; lead investors include Suvretta Capital Management.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 1 | 14% |
| Private equity | 2 | 29% |
| Other / undisclosed | 4 | 57% |